Vanda Pharmaceuticals Receives New Coverage from Analysts at Piper Jaffray (VNDA)
Equities research analysts at Piper Jaffray started coverage on shares of Vanda Pharmaceuticals (NASDAQ: VNDA) in a research note issued to investors on Tuesday. The firm set an “overweight” rating and a $8.00 price target on the stock.
A number of other analysts have also recently weighed in on VNDA. Analysts at Jefferies Group upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a research note to investors on Thursday, February 14th. They now have a $6.00 price target on the stock, up previously from $3.50. Separately, analysts at Lazard Capital Markets initiated coverage on shares of Vanda Pharmaceuticals in a research note to investors on Tuesday, February 5th. They set a “buy” rating and a $11.00 price target on the stock. Finally, analysts at JMP Securities initiated coverage on shares of Vanda Pharmaceuticals in a research note to investors on Thursday, January 17th. They set an “outperform” rating and a $9.00 price target on the stock.
Shares of Vanda Pharmaceuticals traded up 1.08% during mid-day trading on Tuesday, hitting $3.74. Vanda Pharmaceuticals has a 52 week low of $2.92 and a 52 week high of $5.23. The stock’s 50-day moving average is currently $4.01. The company’s market cap is $106.0 million.
Vanda Pharmaceuticals last announced its earnings results on Tuesday, February 12th. The company reported ($0.23) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.22) by $0.01. The company had revenue of $7.90 million for the quarter, compared to the consensus estimate of $8.60 million. During the same quarter in the prior year, the company posted ($0.20) earnings per share. The company’s quarterly revenue was down 6.0% on a year-over-year basis. On average, analysts predict that Vanda Pharmaceuticals will post $-0.89 earnings per share for the current fiscal year.
Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.